Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
5.03%
Operating Margin
81.00%
Net Margin
12.27%
Efficiency Metrics
Revenue per Expense Ratio
5.26
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
0.1300000000
Balance Sheet Analysis
Current Ratio
2.32
Cash Ratio
0.12
Working Capital
$79.30M
Debt to Equity
0.78
Debt to Assets
43.16%
Equity Ratio
55.43%
Cash Flow Analysis
Operating Cash Flow Ratio
88.48%
Free Cash Flow Ratio
88.48%
CapEx to Revenue
0.00%
Dividends Paid
$116.44M
Stock Buybacks
$138.00M
Total Shareholder Returns
$254.44M
Cash Position Change
-84.44%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
124.72%
Net Income
102.99%
EPS
103.04%
Operating Income
120.25%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
211.05%
Operating Cash Flow
-24.66%
Free Cash Flow
-24.66%
Balance Sheet Health
Assets
-3.52%
Debt
359,703.56%
Book Value per Share
-3.33%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-32.77%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
111.56%
5Y Revenue/Share
8,568.06%
3Y Dividend/Share
-33.40%
5Y Dividend/Share
-35.71%